Navigation

Navigation

Physician Profile


<< Previous Physician | Return to Search Results | New Search | Next Physician >>


George Z. Retsch-Bogart, MD

Associate Professor; Chief, Division of Pediatric Pulmonology; Medical Director, N.C. Children's Airway Center

Curriculum Vitae

Department of Pediatrics
    Division of Pulmonology

Services:
Pediatrics, Pulmonology
Medicine, UNC Cystic Fibrosis Center

Procedures/Research:
Cystic fibrosis; chronic lung disease; flexible bronchoscopy; complex airway disorders in children; and clinical research in cystic fibrosis.
 
Clinical Appointment Phone:  919-966-1401

Website: http://www.ncchildrenshospital.org/ourservices/specialties/pulmonology
George Z. Retsch-Bogart, MD


Certifications
Pediatric Pulmonology - Board Certified  (1989)
Pediatrics - Board Certified  (1984)


Education and Training
Fellowship: University of North Carolina, Chapel Hill, NC, 1986 - 1989
Area: Pediatric Pulmonology
Residency: University of Minnesota Hospitals, Minneapolis, Minnesota, 1978 - 1981
Area: Pediatrics
Medical School: MD, University of Cincinnati, Cincinnati, Ohio, 1978


Honors
  1. The Best Doctors in America®, 2005-2009

  2. Harry Shwachman Clinical Investigator Award, Cystic Fibrosis Foundation, 1989

  3. Thomas H. Davis Fellowship, American Lung Association of North Carolina, 1988

  4. Research Award, University of North Carolina Department of Pediatrics, 1988


Publications
  1. Eradication of initial Pseudomonas aeruginosa infection in children with Cystic Fibrosis – What is the optimal treatment approach?
    Authors: Treggiari MM, Rosenfeld M, Retsch-Bogart G, Gibson R, Ramsey B
    Pediatr Pulmonol 2007 42(9): 104-12., 2007

  2. Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis
    Authors: McCoy KS, AL Quittner, CM Oermann, RL Gibson, GZ Retsch-Bogart, AB Montgomery
    Am J Respir Crit Care Med. 2008, 178: 921-928. , 2008

  3. A Phase 2 study of Aztreonam Lysinate for Inhalation to treat cystic fibrosis patients with Pseudomonas aeruginosa infection
    Authors: Retsch-Bogart GZ, Burns J, Markus R, Gibson R for the CF TDN Aztreonam for Inhalation Phase 2 Study Group
    Pediatr Pulmonol 2008, 43:47-58., 2008

  4. Early anti-pseudomonal intervention in young patients with cystic fibrosis (EPIC): rationale and design of the clinical trial and observational study
    Authors: Treggiari M, Rosenfeld M, Retsch-Bogart G, Gibson RL, Meyer-Hamblett N, Williams J, Emerson J, Kronmal R, Ramsey B for the EPIC Study Group
    Contemp Clin Trials. 2009; 30: 256-268., 2009

  5. Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis
    Authors: Retsch-Bogart GZ, AL Quittner. RL Gibson, CM Oermann, KS McCoy, AB Montgomery, PJ Cooper
    Chest. 2009; 135: 1223-1232. , 2009

  6. Update on Cystic Fibrosis-Related Bone Disease: A Special Focus on Children
    Authors: Sermet-Gaudelus I, Castanet M, Retsch-Bogart G, Aris RM
    Paediatr Respir Rev. 2009; 10:134-142., 2009

  7. Update on new pulmonary therapies
    Authors: Retsch-Bogart GZ
    Curr Opin Pulm Med. 2009 Aug 19. [Epub ahead of print]., 2009


Abstracts
  1. Sustained Improvement In Pulmonary Function Following A 28-day Course Of 75 mg AZLI TID Therapy
    Authors: G Retsch-Bogart, K McCoy, RL Gibson, C Oermann, M Braff, AB Montgomery
    Pediatr Pulmonol 2008., 2008

  2. Source of Improvements in Lung Function in Patients with Cystic Fibrosis (CF) Following Treatment with Aztreonam Lysine for Inhalation (AZLI)
    Authors: G Retsch-Bogart, K McCoy, R Gibson, C Oermann, AB Montgomery
    Pediatr Pulmonol 2008., 2008

  3. Effect of multiple courses of Aztreonam Lysine for Inhalation (AZLI) on FEV1 and weight in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): Analysis of 18 month data from CP-AI-006
    Authors: Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, Montgomery AB J Cystic Fibrosis, 2009, A107
    J Cystic Fibrosis, 2009, A107., 2009

  4. Efficacy of Aztreonam Lysine for Inhalation (AZLI) in patients with cystic fibrosis and drug resistant P. aeruginosa (DRPA)
    Authors: McCoy KS, Retsch-Bogart GZ, Gibson RL, Oermann CM, McKevitt M, Montgomery AB
    J Cystic Fibrosis, 2009, A108., 2009

  5. Adherence over multiple courses of Aztreonam Lysine for Inhalation (AZLI): effect on disease-related endpoints in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA)
    Authors: Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, Quittner, AL, Montgomery AB
    J Cystic Fibrosis, 2009, A109., 2009


Physician Referral:
You can request a physician referral by calling UNC HealthLink at (919) 966-7890,
8:30 a.m. to 5 p.m., Monday through Friday.